Business Context and Reporting Period
This Form 8-K is a current report filed by Flex Pharma, Inc. (not Decoy Therapeutics Inc.) on June 8, 2018, regarding events occurring on June 6, 2018. The filing details the results of the Company's Annual Meeting of Stockholders. The registrant is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results and does not contain financial performance data.
Material Changes and Voting Results
The primary material event reported is the outcome of two stockholder proposals at the Annual Meeting:
- Proposal 1 (Election of Directors): Stockholders elected Mr. Peter Barton Hutt as the Class III director nominee.
- Votes For: 11,632,922
- Votes Withheld: 601,756
- Broker Non-Votes: 1,971,617
- Proposal 2 (Ratification of Auditors): Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the year ending December 31, 2018.
- Votes For: 14,132,390
- Votes Against: 62,956
- Abstentions: 10,949
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the reporting of voting tallies.
Important Facts for Investors to Verify
- Confirm the registrant name is Flex Pharma, Inc., as the input metadata referenced Decoy Therapeutics Inc.
- Verify the tenure of the newly elected Class III director, Mr. Peter Barton Hutt, which extends until the 2021 Annual Meeting.
- Review the definitive proxy statement on Schedule 14A filed on April 23, 2018, for detailed background on the proposals.
- Note the significant number of broker non-votes (1,971,617) on the director election, which may indicate specific voting instructions were not provided by brokers.